ID: ALA5271846

Max Phase: Preclinical

Molecular Formula: C35H40Cl3N5O4

Molecular Weight: 701.10

Representations

Canonical SMILES:  CCN[C@H](CC(=O)N[C@H]1CCc2ccccc2N(CC(=O)N[C@@H](CC(=O)NC)Cc2ccc(Cl)c(Cl)c2)C1=O)Cc1ccc(Cl)cc1

Standard InChI:  InChI=1S/C35H40Cl3N5O4/c1-3-40-26(16-22-8-12-25(36)13-9-22)19-33(45)42-30-15-11-24-6-4-5-7-31(24)43(35(30)47)21-34(46)41-27(20-32(44)39-2)17-23-10-14-28(37)29(38)18-23/h4-10,12-14,18,26-27,30,40H,3,11,15-17,19-21H2,1-2H3,(H,39,44)(H,41,46)(H,42,45)/t26-,27+,30-/m0/s1

Standard InChI Key:  VARFVEOJGJTSSJ-DURBRWELSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type:

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 701.10

Molecular Weight (Monoisotopic): 699.2146

AlogP: 4.89

#Rotatable Bonds: 14

Polar Surface Area: 119.64

Molecular Species: BASE

HBA: 5

HBD: 4

#RO5 Violations: 1

HBA (Lipinski): 9

HBD (Lipinski): 4

#RO5 Violations (Lipinski): 1

CX Acidic pKa: 12.45

CX Basic pKa: 9.51

CX LogP: 4.75

CX LogD: 2.67

Aromatic Rings: 3

Heavy Atoms: 47

QED Weighted: 0.19

Np Likeness Score: -0.64

References

1. Johannes JW, Bates S, Beigie C, Belmonte MA, Breen J, Cao S, Centrella PA, Clark MA, Cuozzo JW, Dumelin CE, Ferguson AD, Habeshian S, Hargreaves D, Joubran C, Kazmirski S, Keefe AD, Lamb ML, Lan H, Li Y, Ma H, Mlynarski S, Packer MJ, Rawlins PB, Robbins DW, Shen H, Sigel EA, Soutter HH, Su N, Troast DM, Wang H, Wickson KF, Wu C, Zhang Y, Zhao Q, Zheng X, Hird AW..  (2017)  Structure Based Design of Non-Natural Peptidic Macrocyclic Mcl-1 Inhibitors.,  8  (2): [PMID:28197319] [10.1021/acsmedchemlett.6b00464]

Source

Source(1):

• Scientific Literature